Loading...
XNAS
VYGR
Market cap177mUSD
Jul 29, Last price  
3.20USD
1D
-2.14%
1Q
-10.11%
Jan 2017
-74.88%
IPO
-81.71%
Name

Voyager Therapeutics Inc

Chart & Performance

D1W1MN
P/E
—
P/S
2.21
EPS
—
Div Yield, %
—
Shrs. gr., 5y
9.94%
Rev. gr., 5y
-5.18%
Revenues
80m
-68.00%
0017,334,00014,220,00010,135,0007,619,000104,391,000171,128,00037,415,00040,907,000250,008,00080,001,000
Net income
-65m
L
-7,666,000-16,317,000-29,672,000-40,193,000-70,698,000-88,288,000-40,832,00036,741,000-66,032,000-46,408,000132,330,000-65,002,000
CFO
-15m
L
-5,450,000-11,918,00041,299,000-42,482,000-61,350,000-15,887,00048,666,000-96,716,000-53,525,000-12,509,00077,919,000-15,310,000
Earnings
Aug 04, 2025

Profile

Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
URL
https://www.voyagertherapeutics.com/
IPO date
Nov 11, 2015
Employees
125
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
80,001
-68.00%
250,008
511.16%
40,907
9.33%
Cost of revenue
163,288
132,435
97,935
Unusual Expense (Income)
NOPBT
(83,287)
117,573
(57,028)
NOPBT Margin
47.03%
Operating Taxes
665
1,408
16
Tax Rate
1.20%
NOPAT
(83,952)
116,165
(57,044)
Net income
(65,002)
-149.12%
132,330
-385.14%
(46,408)
-29.72%
Dividends
Dividend yield
Proceeds from repurchase of equity
112,778
31,121
1,591
BB yield
-34.49%
-8.27%
-0.68%
Debt
Debt current
7,227
3,200
2,832
Long-term debt
80,225
37,386
43,420
Deferred revenue
32,359
6,450
Other long-term liabilities
7,003
1,001
1,001
Net debt
(179,232)
(191,882)
(74,111)
Cash flow
Cash from operating activities
(15,310)
77,919
(12,509)
CAPEX
(3,521)
(3,256)
(2,491)
Cash from investing activities
(94,859)
(141,643)
(7,339)
Cash from financing activities
114,015
33,645
1,110
FCF
(74,110)
92,002
(35,008)
Balance
Cash
266,684
230,875
118,848
Long term investments
1,593
1,515
Excess cash
262,684
219,968
118,318
Stockholders' equity
(326,536)
(261,186)
(393,693)
Invested Capital
677,025
551,159
483,290
ROIC
22.46%
ROCE
40.55%
EV
Common stock shares outstanding
57,668
44,569
38,357
Price
5.67
-32.82%
8.44
38.36%
6.10
125.09%
Market cap
326,975
-13.08%
376,165
60.77%
233,977
129.20%
EV
147,743
184,283
159,866
EBITDA
(78,556)
122,014
(50,837)
EV/EBITDA
1.51
Interest
1,792
Interest/NOPBT